This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Medlab Clinical 将来の成長

Future 基準チェック /26

We currently don't have sufficient analyst coverage to forecast growth and revenue for Medlab Clinical.

主要情報

-44.7%

収益成長率

-44.7%

EPS成長率

Biotechs 収益成長	15.3%
収益成長率	41.7%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	04 May 2023

今後の成長に関する最新情報

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Nov 22

Recent updates

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Oct 06

業績と収益の成長予測

ASX:MDC - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2024	4	-22	N/A	N/A	1
6/30/2023	7	-14	N/A	N/A	1
6/30/2022	2	-8	-9	-9	N/A
3/31/2022	1	-9	-10	-10	N/A
12/31/2021	4	-12	-11	-11	N/A
9/30/2021	4	-12	-11	-11	N/A
6/30/2021	1	-10	-10	-10	N/A
3/31/2021	1	-10	-9	-9	N/A
12/31/2020	1	-11	-8	-8	N/A
9/30/2020	2	-12	-10	-9	N/A
6/30/2020	3	-13	-11	-10	N/A
3/31/2020	4	-12	-11	-11	N/A
12/31/2019	4	-12	-12	-12	N/A
9/30/2019	5	-10	-11	-11	N/A
6/30/2019	5	-8	-11	-10	N/A
3/31/2019	5	-7	-9	-9	N/A
12/31/2018	5	-6	-7	-7	N/A
9/30/2018	4	-5	-6	-6	N/A
6/30/2018	4	-5	-5	-5	N/A
3/31/2018	4	-4	-5	-5	N/A
12/31/2017	5	-4	-5	-5	N/A
9/30/2017	5	-4	-4	-4	N/A
6/30/2017	4	-4	-4	-4	N/A
3/31/2017	4	-4	-4	-4	N/A
12/31/2016	4	-4	-4	-4	N/A
9/30/2016	3	-4	-4	-4	N/A
6/30/2016	3	-3	-4	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MDC is forecast to remain unprofitable over the next 3 years.

収益対市場: MDC is forecast to remain unprofitable over the next 3 years.

高成長収益: MDC is forecast to remain unprofitable over the next 3 years.

収益対市場: MDC's revenue (41.7% per year) is forecast to grow faster than the Australian market (4.8% per year).

高い収益成長: MDC's revenue (41.7% per year) is forecast to grow faster than 20% per year.

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: Insufficient data to determine if MDC's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Medlab Clinical 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Recent updates

Consensus EPS estimates upgraded to AU$2.29 loss, revenue downgraded

Consensus forecasts updated

Price target decreased to AU$18.84

Medlab Announces Interim Readout of Rwe Medcare Study

Medlab Clinical Limited Receives UK Import Permission from MHRA for Nanabis

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Medlab Clinical Limited Provides NanoCelle Nasal RNA (Nucleid Acid) Program Update

Medlab Clinical Limited Provides NanaBis and NanoCBD Clinical Development Update

Less than half of directors are independent

Medlab Clinical Limited Announces the Resignation of Laurence McAllister as Non-Executive Director

Full year 2022 earnings: Revenues exceed analyst expectations

Medlab Clinical Limited, Annual General Meeting, Sep 30, 2022

Medlab Clinical Ltd Announces the European Patent Office Has Formalised ACCEPTANCE of the Depression Patent, and Within the Next 2-3 Months Will Be Granted

Medlab Clinical Limited Appoints Mohit Gupta as an Independent Non-Executive Director, Effective August 8, 2022

Medlab Clinical Ltd Updates Shareholders on the Progress of Our NanoCelle NanaBis Program

Medlab Clinical Ltd Announces Update on Progression of NanoCelle NASAL COVID-19 Vaccine Program

Less than half of directors are independent

Medlab Clinical Ltd Announces Update on NanoCBDTM

Medlab Clinical Ltd Announces the Receipt of "Favorable Opinion" Status from the UK Research Ethics Committee for the Forthcoming Nanabistm Phase 3 Trial, with No Additional Conditions or Submission Required

Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now

Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?

Full year 2021 earnings released: AU$0.042 loss per share (vs AU$0.059 loss in FY 2020)

Medlab Receives Phase 3 NanaBi Trials Approval from the Australian Government, with Clinical Trials Number for Cancer Bone Pain

Australian Ethics Grants Approval for Medlab's NanaBisTM PIII Australian Sites

CFO, Company Secretary & COO has left the company

Medlab Clinical Limited announced that it expects to receive AUD 15 million in funding

Medlab Clinical Limited Appoints Cheryl Maley as an Independent Non-Executive Director

First half 2021 earnings released: AU$0.019 loss per share (vs AU$0.033 loss in 1H 2020)

What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay

Medlab Executes Australian Exclusive Non-Binding Heads of Agreement with Arrotex Australia Group Australia Pty Ltd

Medlab Clinical Limited Receives Positive Depression Trial Prelim Results

New 90-day high: AU$0.36

Medlab Clinical Announces US FDA Grants Investigational New Drug (IND) Status for Nanabistm

Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years

Medlab Clinical Provides an Update on Clinical and Pre-Clinical Programs Currently Underway

Medlab Clinical Limited Announces NanaBis Observational Study Progression Report

New 90-day high: AU$0.26

Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future

Medlab Clinical Limited Announces NanaBisTM PIII Trial Launching in the Uk with Support from the National Institute for Health Research

New 90-day high: AU$0.21

Full year earnings released - AU$0.059 loss per share

Medlab Clinical Limited has completed a Follow-on Equity Offering in the amount of AUD 1.570476 million.

Medlab Clinical Limited announced that it has received AUD 5.397603 million in funding

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘